39 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
injury in patient with AATD may be due to inadequately controlled NE caused by insufficient alpha-1 antitrypsin (AAT). We believe that by inhibiting NE … , liability claims may result in:
decreased demand for our product candidates;
injury to our reputation;
withdrawal of clinical trial participants;
costs
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
liability for death or personal injury caused by a Party's negligence.
8.4All indemnification claims in respect of a Party, its Affiliates … . The Parties agree that any such breach or threatened breach would cause irreparable injury, that the remedies at law for any such breach or threatened breach
S-8
EX-99.1
a87gqkix0bjbmw63xgu7
15 Jan 21
Registration of securities for employees
4:21pm
S-8
EX-99.6
2rxn8xa
15 Jan 21
Registration of securities for employees
4:21pm
S-8
EX-99.5
u4n o6ppdt9zk
15 Jan 21
Registration of securities for employees
4:21pm
6-K
EX-99.2
4tp2fergb8oab5tij
29 Sep 20
Current report (foreign)
7:08am
6-K
EX-99.1
y3bllmz bjzbwlkoa
25 Aug 20
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
11:14am